Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical Indus is attractive because its Pivot to Growth strategy is steadily shifting the company from a generics-led model toward higher-margin branded medicines, with AUSTEDO, UZEDY, and AJOVY already driving meaningful commercial momentum. The pipeline adds further upside through late-stage assets such as duvakitug and LAI olanzapine, while the generics and biosimilars businesses remain durable, supported by 101 product applications and more than $66Bn of first-to-file branded sales opportunities. Financially, the company reported 1Q26 revenue of $4.0B and EBITDA of $1.1B, with net debt/EBITDA improving to 2.4x, reinforcing improving execution, margin expansion, and balance-sheet discipline.

Teva Pharmaceutical Indus is viewed negatively because its core recovery depends on multiple execution-sensitive drivers that may not materialize, including AUSTEDO maintaining share through 2029, biosimilar revenue doubling by 2027, and a meaningful generic rebound after the Revlimid headwind. The thesis is also vulnerable to launch and regulatory risk, since the olanzapine LAI outlook assumes a PDSS-free label, while the January 1, 2027 Medicare Part D price cut on AUSTEDO could pressure revenue even as management guided Q4’26 AUSTEDO revenue down and 2026 sales to $2,450-2,600MM. In addition, material opioid, price-fixing, and environmental contingencies, plus potential underperformance in duvakitug and other pipeline assets, threaten earnings, cash flow, and de-levering.